Evotec and Merck KGaA to Collaborate on Neurological Disease Target

Evotec agrees to collaborate with Merck KGaA within the NEU2-Consortium (http://www.neu-quadrat.de/start-en.html) composed of academic, pharma and biotech centers. The collaboration seeks to harness Evotec’s drug discovery expertise for the development of pre-clinical drug candidates for neurological diseases.

Click here to read more.

Share this: